GlassScriptPhysician profile
James R Spurlock
NPI 1376544767
$6,003.14
in general payments reported to CMS, 2019-2025
38 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $947 · 2021: $748 · 2022: $1,000 · 2023: $990 · 2024: $856 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,070.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $934.80 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $712.05 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $426.09 | 2019-2025 | |
| Lilly USA, LLC | $424.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $335.27 | 2021-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $318.25 | 2019-2025 | Trintellix |
| Allergan, INC. | $278.19 | 2019-2020 | |
| Astellas Pharma US INC | $168.77 | 2019-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $166.38 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $155.53 | 2019-2024 | Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $124.11 | 2023-2025 | |
| Glaxosmithkline, LLC. | $121.80 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $91.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55.08 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Spurlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.